Evidence map›Paper›PMID 28650953›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2017

De Novo Paternal FBN1 Mutation Detected in Embryos Before Implantation.

Shuling Wang, Ziru Niu, Hui Wang, Minyue Ma, Wei Zhang, Shu Fang Wang, Jun Wang, Hong Yan, Yifan Liu, Na Duan and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. [Latest advances in the diagnosis and treatment of Marfan syndrome].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022
    Review
  4. The Molecular Genetics of Marfan Syndrome.International journal of medical sciences · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Shuling WangReproductive Center, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China (mainland).
Ziru NiuDepartment of Obstetrics and Gynecology, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China (mainland).
Hui WangReproductive Center, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China (mainland).
Minyue MaReproductive Center, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China (mainland).
Wei ZhangBeijing Genomics Institute Shenzhen (BGI-Shenzhen), Shenzhen, Guangdong, China (mainland).
Shu Fang WangDepartment of Blood Transfusion, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China (mainland).
Jun WangClinical Laboratory of Beijing Genomics Institute Health, BGI-Shenzhen, Shenzhen, Guangdong, China (mainland).
Hong YanDepartment of Obstetrics and Gynecology, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China (mainland).
Yifan LiuReproductive Center, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China (mainland).
Na DuanMedical College, Nankai University, Tianjin, China (mainland).
Xiandong ZhangReproductive Center, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China (mainland).
Yuanqing YaoReproductive Center, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China (mainland).
Chinese PLA General Hospital · CNBGI Group (China) · CNNankai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Marfan syndrome (MFS) is an autosomal dominant disease caused by mutations in the Fibrillin (FBN)1 gene and characterized by disorders in the cardiovascular, skeletal, and visual systems. The diversity of mutations and phenotypic heterogeneity of MFS make prenatal molecular diagnoses difficult. In this study, we used pre-implantation genetic diagnosis (PGD) to identify the pathogenic mutation in a male patient with MFS and to determine whether his offspring would be free of the disease. MATERIAL AND METHODS The history and pedigree of the proband were analyzed. Mutation analysis was performed on the couple and immediate family members. The couple chose IVF treatment and 4 blastocysts were biopsied. PGD was carried out by targeted high-throughput sequencing of the FBN1 gene in the embryos, along with single-nucleotide polymorphism haplotyping. Sanger sequencing was used to confirm the causative mutation. RESULTS c.2647T>C (p.Trp883Arg) was identified as the de novo likely pathogenic mutation in the proband. Whole-genome amplification and sequencing of the 3 embryos revealed that they did not carry the mutation, and 1 blastocyst was transferred back to the uterus. The amniocentesis test result analyzed by Sanger sequencing confirmed the PGD. A premature but healthy infant free of heart malformations was born. CONCLUSIONS The de novo mutation c.2647T>C (p.Trp883Arg) in FBN1 was identified in a Chinese patient with MFS. Embryos without the mutation were identified by PGD and resulted in a successful pregnancy.

Indexed as

AdipokinesAllelesBase SequenceDNADNA Mutational AnalysisEmbryo ImplantationEmbryo, MammalianFamilyFemaleFibrillin-1HaplotypesHigh-Throughput Nucleotide SequencingHumansMaleMarfan SyndromeMutationAdipokinesDNAFBN1 protein, humanFibrillin-1

Identifiers

PMID28650953
PMCPMC5498129
OpenAlexW2676196386

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.